TRPV1 receptors are activated and/or modulated by noxious heat, capsaicin, protons and other endogenous agents released following tissue injury. There is a growing appreciation that this molecular integrator may also have a role in mechanosensation. In order to further understand this role, we investigated the systemic and site-specific effects of a selective TRPV1 receptor antagonist, A-889425, on low-intensity mechanical stimulation in inflamed rats. Systemic administration of A-889425 (30 and100 µmol/kg, p.o.) reduced mechanical allodynia in complete Freund's adjuvant (CFA)-inflamed rats. 
INTRODUCTION
The transient receptor potential vanilloid type1, TRPV1, plays an important role in nociceptive transmission and modulation (Numazaki and Tominaga, 2004) . These receptors are considered molecular integrators due to their heterologous activation and/or sensitization by noxious heat, protons and other endogenous matter released following tissue injury (Caterina et al., 1997; Chuang et al., 2001; Tominaga et al., 1998 Tominaga et al., , 2001 Vellani et al., 2001; Vyklicky et al., 1998) . TRPV1 gene-ablated (TRPV1 -/-) mice show reduced sensitivity to thermal stimulation after the induction of inflammation (Caterina et al., 2000; Davis et al., 2000) . Furthermore, administration of selective TRPV1 receptor antagonists reduces the transmission of high-intensity thermal stimulation in uninjured animals (Kelly and Chapman, 2002; McGaraughty et al., 2006) , and attenuates hyperalgesia and allodynia in a variety of animal models of pathological pain (Cui et al., 2006; Culshaw et al., 2006; Gavva et al., 2005; Honore et al., 2005; Varga et al., 2005) .
The efficacy of TRPV1 receptor antagonists is enhanced in models of pathological pain (Honore et al., 2005; McGaraughty et al., 2006) While it is well accepted that TRPV1 receptors are important mediators of thermal nociception (Tominaga and Caterina, 2004) , it is now only becoming appreciated that TRPV1 receptors may also contribute to mechanotransmission, particularly after the occurrence of an injury. In uninjured TRPV1
-/-mice, behavioral responses to mechanical stimulation were not different from the responses of wild-type mice (Caterina et al., 2000) . However, the mechanical thresholds of TRPV1 -/-mice with inflammation were significantly higher than similarly inflamed wild-type mice (Szabo et al., 2005) .
Additionally, systemic administration of different TRPV1 receptor antagonists reduces mechanical allodynia and hyperalgesia in animal models of neuropathic, inflammatory and post-operative pain (Cui et al., 2006; Culshaw et al., 2006; Honore et al., 2005; Pomonis et al., 2003) . TRPV1-related modulation of mechanical sensitivity can be mediated by TRPV1 receptors in both the spinal cord and peripheral tissue (Cui et al., 2006; Gaava et al., 2005; Honore et al., 2005; Kanai et al., 2005) . Although TRPV1
receptors are also expressed in supraspinal sites that are implicated in nociceptive modulation (for a review see McGaraughty and Bitner, 2007) , it is unknown if these have any role in the modulation of mechanotransmission.
In the current study, we examined the effects of a systemically administered TRPV1 receptor antagonist, A-889425 (Figure 1 ), on the responses of spinal WDR neurons to low-intensity mechanical stimulation in inflamed and uninjured rats. A-889425 (Brown et al., 2008 ) is a selective TRPV1 receptor antagonist with an IC 50 of 335 nM to displace capsaicin at rat receptors, and has good penetration into the CNS. In additional experiments, A-889425 was injected into the spinal cord, cerebral ventricles and neuronal receptive field (RF) in order to determine if blockade of receptors at these sites alters the responses of WDR neurons to low-intensity mechanical stimulation.
Finally, we examined the systemic and site-specific actions of A-889425 on spontaneous WDR neuronal firing. We have previously reported that systemic administration of A-425619, a TRPV1 receptor antagonist with poor CNS penetration, does not alter the spontaneous firing of WDR neurons in inflamed rats (McGaraughty et al., 2006) .
MATERIALS AND METHODS
All animal handling and experimental protocols were approved by Abbott's and unpublished data), and thus is selective for TRPV1 receptors.
Behavioral experiments
Chronic inflammation was induced by injecting complete Freund's adjuvant (CFA, 50%, 150 μl) into the plantar surface of the rat's right hindpaw 48 hours prior to administration of A-889425 (10-100 µmol/kg, p.o.) or vehicle (polyethylene glycol).
Tactile allodynia was determined by measuring paw withdrawal in response to stimulation with a series of von Frey filaments (Stoelting, Wood Dale, IL) using the updown method described by Dixon (1980) . Briefly, rats were placed on an elevated mesh bottom floor with a 1.27 X 1.27 cm6
hindpaws. An inverted, clear plastic cage (29 X 18 X 12 cm) was placed over each rat.
The von Frey filament was presented perpendicular to the plantar surface of the left hindpaw, and held in this position for approximately 8 seconds with enough force to cause a slight buckle in the filament. Positive responses included sharp withdrawal or flinching behavior during stimulation. Only those rats with a mean baseline threshold score of less than 4.5 g were used in this study. To confirm allodynia, both inflamed and
non-inflamed hindpaws were tested up to a maximum force of 15 g prior to administration of A-889425 or vehicle.
Electrophysiological experiments
As with behavioral testing, CFA (150 µl) was injected into the plantar region of the rat's right hindpaw 48 hrs prior to electrophysiological experiments. On the day of neuronal recording, CFA-inflamed and non-inflamed animals were initially anesthetized with pentobarbital (50 mg/kg, i.p. 
Data analysis
For the behavioral experiments, statistical significance on group means was measured by an ANOVA followed by a Fisher's PLSD post-hoc analysis (p < 0.05). In electrophysiology experiments, baseline levels of neuronal spontaneous and evoked firing in inflamed and uninjured rats were compared using a t-test (p < 0.05). For each neuron, the post-drug spontaneous and evoked activity was calculated as a percent of the respective baseline levels. For comparisons to baseline firing levels, statistical significance was established by using a Wilcoxon's matched-pairs test. A Kruskal-Wallis analysis of variance followed by a Mann-Whitney U test was used for comparison across groups in both electrophysiological and behavioral experiments (p < 0.05). All data are presented as mean ± SEM
RESULTS

Behavioral effects of A-889425
In vehicle-treated rats, the threshold for withdrawal from von Frey hair stimulation to the inflamed hindpaw was 3.8 ± 0. higher level of spontaneous firing that was observed in the CFA-inflamed rats is an indication of neuronal sensitization Chu et al., 2004; Suzuki and Dickenson, 2006) . Application of the 10-g von Frey hair stimulus for 15 sec to the neuronal receptive field evoked similar levels of baseline activity in CFA-inflamed (15.96 ± 0.83 spikes/sec) and uninjured rats (15.13 ± 4.11 spikes/sec) and is consistent with previous reports (Carpenter et al., 2000; Elmes et al., 2004; Kelly & Chapman, 2003; Sokal et al., 2003) .
Effects of systemic A-889425 on WDR neuronal activity
Systemic administration (i.v.) of A-889425 (1-10 µmol/kg) dose-dependently attenuated both spontaneous and von Frey-evoked firing of WDR neurons in CFAinflamed but not uninjured rats (Figure 3 ). Within 5 min of injection, 3 and 10 µmol/kg of A-889425 significantly (p<0.05) decreased neuronal responses to 10-g von Frey hair stimulation by 30.22 ± 7.04 % and 58.18 ± 9.62 %, respectively, from baseline levels in inflamed animals ( Fig 3A) . Effects of A-889425 on spontaneous WDR activity (p<0.05)
were delayed compared to evoked firing. Injection of 10 µmol/kg of A-889425 to inflamed rats reduced spontaneous firing by 68.17 ± 7.76 % 15 min after injection, while it took up to 25 min for the 3 µmol/kg dose to decrease spontaneous discharges by 45.51 ± 12.87 % (Fig 3B) . The greatest magnitude of effect was observed 35 min after injection of 10 µmol/kg of A-889425, when spontaneous firing was decreased by 73.46 ± 4.52 %, and von Frey-evoked activity was reduced by 82.16 ± 3.69 % from baseline levels. McGaraughty et al., 2003; Starowicz et al., 2007) . The RVM is an integral region involved in descending modulation of spinal nociceptive neurons (Fields, 2000; Heinricher and McGaraughty, 1998) , and may have factored into the attenuation of mechanically evoked WDR neuronal firing after A-889425 administration.
Site-specific effects of A-889425 on WDR neuronal activity
In addition to attenuating mechanically evoked firing, systemic administration of A-889425 also decreased the spontaneous activity of WDR neurons in inflamed but not uninjured rats. Consistent with previous data from our group as well as others, the ongoing firing of WDR neurons becomes significantly elevated following a peripheral injury Chu et al., 2004 Chu et al., , 2007 McGaraughty et al., , 2008 Suzuki and Dickenson, 2006) . The higher levels of spontaneous WDR neuronal firing likely reflect injury-related sensitization Chu et al., 2004; Suzuki and Dickenson, 2006) , and may indicate the occurrence of chronic unevoked or "nagging" pain in the animal. Spontaneous pain is observed in the majority of patients with chronic pain (Backonja and Stacey, 2004; Birklein et al., 2000) , and is a primary factor in seeking medical care. Drugs that alleviate unevoked pain in humans, such as gabapentin and various opioids (Attal et al., 1998; Jorum et al., 2003; Watson et al., 2003) , decrease spontaneous firing of WDR neurons in rats following a peripheral nerve injury (Suzuki and Dickenson, 2006) . In contrast, administration of an NMDA receptor antagonist, memantine, failed to decrease spontaneous discharges of WDR neurons in injured rats and correspondingly does not affect spontaneous pain in humans (Nikolajsen et al., 2000; Suzuki and Dickenson, 2006) . Since accurate assessment of unevoked pain in animals is difficult (Mogil and Crager, 2004) , examining the ongoing firing of WDR neurons in animal models of pathological pain may provide a biological marker to this endpoint. Thus, the current data suggest that antagonism of TRPV1 receptors may be an effective means to alleviate both evoked and spontaneous pain.
Systemic injection of another TRPV1 receptor antagonist, A-425619, did not reduce the spontaneous discharging of WDR neurons in CFA-inflamed rats (McGaraughty et al., 2006) . It was hypothesized that this lack of effect on spontaneous firing was due to the compound's poor CNS penetration. Consistent with this hypothesis, A-889425 has significantly better CNS penetration (Brown et al., 2008) In addition to TRPV1 receptor antagonists, CB 2 receptor agonists and Nav1.8 channel blockers preferentially utilize spinal mechanisms to reduce spontaneous WDR neuronal firing in animal models of pathological pain , McGaraughty et al., 2008 .
Additionally, spinal delivery of morphine, voltage-dependent calcium channel antagonists, and mexiletine also potently attenuate the spontaneous firing of WDR neurons in injured animals Matthews and Dickenson, 2001a,b; Suzuki and Dickenson, 2006) , but the effects of these compounds on spontaneous firing has not been shown to be limited to the spinal cord. 
